China Factory Supply 99% Purity CAS 16679-58-6 Desmopressin

Superiority:

English name: Desmopressin

CAS number: 16679-58-6

Molecular formula: C46H64N14O12S2

Molecular weight: 1069.22

EINECS Number: 240-726-7

Specific rotation: D25+85.5±2°(calculated for the free peptide)

Density: 1.56±0.1g/cm3(Predicted)

RTECS No.: YW9000000

Storage conditions:Store at 0°C

Solubility:H2O:soluble20mg/mL,clear,colorless

Form: neat

Acidity coefficient: (pKa) 9.90±0.15 (Predicted)

Desmopressin can increase the activity of coagulation factor VIII in plasma and increase the content of vonWillebrand factor antigen. For patients with mild or moderate factor VIII deficiency and type I von Willebrand disease, factor VIII : C is at least 5% of the normal value, may have short-term hemostatic effect. This drug can control mild bleeding episodes (eg, hemoarthrosis, mucosal bleeding, bleeding after tooth extraction), and can also maintain normal coagulation after some major surgery. Before deciding to use desmopressin rather than blood products, the efficacy of the drug and the duration of efficacy should be tested in patients. Desmopressin is not effective in patients with severe factor VIII deficiency, von Willebrand disease III, or factor IX deficiency. Desmopressin has variable efficacy in von Willebrand disease IIA, but should not be used in patients with von Willebrand disease IIB or platelets. Desmopressin may have a transient effect in patients with uremic bleeding who require urgent action. Uremic patients have abnormal platelet-vessel wall interactions, and the effect of desmopressin is thought to be to release vWF polymer stored in endothelial cells outward, increasing catecholamines, which are mediators of hemostatic function, in plasma. concentration. Desmopressin can also temporarily correct abnormal hemostatic function in patients with chronic liver disease or platelet function deficiency. Desmopressin, given before cardiopulmonary bypass, can reduce intraoperative blood loss, and some observational investigators have found that the drug reduces overall blood loss and the need for transfusions. The susceptibility to bleeding in these patients is due to acquired platelet dysfunction. Desmopressin can also reduce intraoperative blood loss and blood transfusion requirements in spinal fusion patients with normal hemostatic function. The drug will be widely used in blood donors to increase factor VIII activity and improve complementary therapy for hemophilia. Desmopressin has the great advantage in all patients that it avoids the risk of hepatitis and HIV infection due to blood products.

(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.

(2) Treatment of nocturnal enuresis (patients aged 5 years or older).

(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.

(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.